Medicament for curing ague completely

Abstract

The invention relates to a medicine for curing and radically curing malaria. The weight parts of the components are: 1 to 5 parts of arteannuin ramification and 5 to 100 parts of large ring lactone antibiotic. The arteannuin ramification can be any artesunate medicine, such as arteannuin, artesunate, artemether or dihydro-arteannuin. The large ring lactone antibiotic can be first, second or third generation large ring lactone antibiotic, such as erythrocin, azithromycin, telithromycin and kui erythrocin. The medicine of the invention is low in poison, safe, rapid in effect, high sufficient and can radically cure malaria, which solves the problem that the after-combustion rate and the recurerence rate of the arteannuin ramification medicine is high after curing malaria; furthermore, the invention is high in medicine safety and has the functions of preventing, curing and blocking spreading of malaria, which is not only suitable for the common malaria infected area, but also more suitable for the infected area with multiple drug fastness malaria, thereby being very safe and effective to the children and pregnant women patients.

Description

technical field [0001] The invention relates to a medicine for treating and radically curing malaria with low toxicity, safety, quick effect and high efficiency. Background technique [0002] Artemisinin and its derivatives are a new class of low-toxicity, safe, quick-acting and highly effective anti-malarial drugs independently developed and produced by China. At present, this type of drug is widely used all over the world. It plays an important role in critically ill malaria patients, and it also has a therapeutic effect on quinine-resistant Plasmodium parasites. In March 2007, the U.S. National Center for Disease Control and Prevention (CDC) announced that the artesunate produced by Guangxi Xiyao Pharmaceutical Factory in China had passed the approval of the U.S. Food and Drug Administration (FDA), and the drug was used as a treatment for critically ill patients with clinical malaria in this country. Rescue drugs to replace long-term use of quinidine. However, a large n...

AI Technical Summary

Problems solved by technology

However, a large number of clinical observation studies have found that artemisinin and its derivatives have a high relapse rate and relapse rate after treating malaria patients. According to research data, malaria patients take 100 mg of artesunate every day. After taking it continuously for 3 days, the symptoms of malaria can be controlled, but the relapse rate after 28 days of observation is 50%; at present, in order to reduce the relapse rate and relapse rate, primaquinine is often used, but due to the side effects of primaquinine are relatively Large, must be used very carefully, the therapeutic effect is unstable

At the same time, the use of artemisinin derivatives is extremely easy to produce drug resistance, which is another problem faced by the application of artemisinin derivatives

Images